1. Home
  2. RHI vs IDYA Comparison

RHI vs IDYA Comparison

Compare RHI & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robert Half Inc.

RHI

Robert Half Inc.

HOLD

Current Price

$30.82

Market Cap

2.8B

ML Signal

HOLD

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$28.15

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RHI
IDYA
Founded
1948
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.6B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
RHI
IDYA
Price
$30.82
$28.15
Analyst Decision
Hold
Strong Buy
Analyst Count
7
16
Target Price
$30.33
$52.86
AVG Volume (30 Days)
1.8M
784.1K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
8.68%
N/A
EPS Growth
N/A
61.90
EPS
0.14
N/A
Revenue
$5,378,506,000.00
$218,710,000.00
Revenue This Year
$1.27
N/A
Revenue Next Year
$5.95
$201.05
P/E Ratio
$221.07
N/A
Revenue Growth
N/A
3024.43
52 Week Low
$21.83
$20.50
52 Week High
$45.17
$39.28

Technical Indicators

Market Signals
Indicator
RHI
IDYA
Relative Strength Index (RSI) 63.52 45.42
Support Level $25.93 $26.05
Resistance Level $35.37 $30.18
Average True Range (ATR) 1.44 1.33
MACD 0.34 0.12
Stochastic Oscillator 82.35 12.24

Price Performance

Historical Comparison
RHI
IDYA

About RHI Robert Half Inc.

Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: